Skip to Content

ReNeuron Group PLC RNUGF

Morningstar Rating
$0.00 0.00 (314.29%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RNUGF is trading at a 297% premium.
Price
$0.00
Fair Value
$3.98
Uncertainty
Extreme
1-Star Price
$1.99
5-Star Price
$2.60
Economic Moat
Ntq
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RNUGF is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.09
Bid/Ask
$0.00 / $810,001.10
Market Cap
$165,803.90
Volume/Avg
150 / 984

Key Statistics

Price/Earnings (Normalized)
Price/Sales
0.54
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
32

Valuation

Metric
RNUGF
Price/Earnings (Normalized)
Price/Book Value
0.06
Price/Sales
0.54
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
RNUGF
Quick Ratio
1.51
Current Ratio
1.51
Interest Coverage
−347.56
Quick Ratio
RNUGF

Profitability

Metric
RNUGF
Return on Assets (Normalized)
−45.11%
Return on Equity (Normalized)
−92.62%
Return on Invested Capital (Normalized)
−88.23%
Return on Assets
RNUGF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
VscbpfcrwNfj$637.8 Bil
Vertex Pharmaceuticals Inc
VRTX
HchwfdzgJvnyyk$121.6 Bil
Regeneron Pharmaceuticals Inc
REGN
CjbmvgxXbdqwf$115.1 Bil
Moderna Inc
MRNA
YshxbymZygd$51.5 Bil
argenx SE ADR
ARGX
MbwrvszfRtdhg$22.9 Bil
BioNTech SE ADR
BNTX
MjkjyhmnjQsdz$20.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
ThpsrcvbKhtyh$19.9 Bil
Biomarin Pharmaceutical Inc
BMRN
XtzrvbndMblxq$16.1 Bil
United Therapeutics Corp
UTHR
ZvtjynkmVxyf$13.7 Bil
Incyte Corp
INCY
NzbldphbJlzynxn$12.3 Bil

Sponsor Center